Relationship between plasma mid-regional pro-adrenomedullin level and resistance to antihypertensive therapy in stable kidney transplant recipients

Peptides

Volumn 48, Issue , 2013, Pages 45-48

  Suzuki, Yosuke ^a   Itoh, Hiroki ^a   Katagiri, Fumihiko ^b   Sato, Fuminori ^c   Kawasaki, Kanako ^a   Sato, Yukie ^a   Sato, Yuhki ^a   Mimata, Hiromitsu ^c   Takeyama, Masaharu ^a  

^a OITA UNIVERSITY HOSPITAL   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^c OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BENIDIPINE; BIOLOGICAL MARKER; BISOPROLOL; CANDESARTAN; CARVEDILOL; CREATININE; ENALAPRIL; FUROSEMIDE; IMIDAPRIL; LOSARTAN; MANIDIPINE; NIFEDIPINE; OLMESARTAN; PROADRENOMEDULLIN; TELMISARTAN; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CREATININE CLEARANCE; ENZYME IMMUNOASSAY; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; MALE; PLASMA; PRIORITY JOURNAL; SCORING SYSTEM;

ADOLESCENT; ADRENOMEDULLIN; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CREATININE; DRUG RESISTANCE; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; RENAL INSUFFICIENCY; TRANSPLANTATION;

EID: 84882752470     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2013.08.001     Document Type: Article

References (19)

1. Bailey KR, Grossardt BR, Graves JW. Novel use of Kaplan-Meier methods to explain age and gender differences in hypertension control rates. Hypertension 2008;51:841-7. (Pubitemid 351654693)
2. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
3. Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, von Eckardstein A, et al. Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD study. Kidney Int 2009;75:408-14.
4. Gouya G, Sturm G, Lamina C, Zitt E, Freistätter O, Struck J, et al. The association of mid-regional pro-adrenomedullin and mid-regional pro-atrial natriuretic peptide with mortality in an incident dialysis cohort. PLoS One 2011;6:e17803.
5. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000;21:138-67. (Pubitemid 32275593)
6. Hirata Y, Mitaka C, Sato K, Nagura T, Tsunoda Y, Amaha K, et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metab 1996;81:1449-53. (Pubitemid 26118575)
7. Kato J, Kitamura K, Eto T. Plasma adrenomedullin level and development of hypertension. J Hum Hypertens 2006;20:566-70. (Pubitemid 44088958)
8. Kitagawa T, Shimozono T, Aikawa T, Yoshida T, Nishimura H. Preparation and characterization of hetero-bifunctional cross-linking reagents for protein modifications. Chem Pharm Bull 1981;29:1130-5.
9. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192:553-60. (Pubitemid 23227359)
10. Kobayashi K, Kitamura K, Etoh T, Nagatomo Y, Takenaga M, Ishikawa T, et al. Increased plasma adrenomedullin levels in chronic congestive heart failure. Am Heart J 1996;131:994-8. (Pubitemid 26135766)
11. Linscheid P, Seboek D, Zulewski H, Keller U, Müller B. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology 2005;146:2699-708. (Pubitemid 40695573)
12. Meeran K, O'Shea D, Upton PD, Small CJ, Ghatei MA, Byfield PH, et al. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab 1997;82:95-100. (Pubitemid 27021277)
13. Nishikimi T. Adrenomedullin in the kidney-renal physiological and pathophysiological roles. Curr Med Chem 2007;14:1689-99. (Pubitemid 47010156)
14. Pio R, Martinez A, Unsworth EJ, Kowalak JA, Bengoechea JA, Zipfel PF, et al. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem 2001;276:2292-300.
15. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004;25:1369-72. (Pubitemid 39180069)
16. Suzuki Y, Itoh H, Katagiri F, Sato F, Sato Y, Kawasaki K, et al. Development and clinical application of an enzyme immunoassay for the determination of midregional proadrenomedullin. J Pept Sci 2013;19:59-63.
17. Suzuki Y, Itoh H, Katagiri F, Sato F, Kawasaki K, Sato Y, et al. Significant decrease in plasma midregional proadrenomedullin level in patients with end-stage renal disease after living kidney transplantation. Peptides 2013;43:102-4.
18. Xu D, Chen W, Li X, Zhang Y, Li X, Lei H, et al. Factors associated with blood pressure control in hypertensive patients with coronary heart disease: evidence from the Chinese cholesterol education program. PLoS One 2013;8: e63135.
19. Yoshihara F, Ernst A, Morgenthaler NG, Horio T, Nakamura S, Nakahama H, et al. Midregional proadrenomedullin reflects cardiac dysfunction in haemodialysis patients with cardiovascular disease. Nephrol Dial Transplant 2007;22:2263-8. (Pubitemid 47244704)